Mode
Text Size
Log in / Sign up
N/A Completed N=34 Randomized Single-blind Diagnostic

Hypotension Prediction Index to Predict Epidural-labor Analgesia Induced Hypotension

Anesthesia, Epidural · Hypotension
Source: ClinicalTrials.gov NCT05906368 ↗
Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcomePrimary: Time-to-treatment of Hypotension (Minutes) — 21.8; 23.1 minutes

Summary

The purpose of this pilot trial is to examine the feasibility and ease of use of monitoring by ClearSight in laboring and delivering patients with the intent to compare time-to-treatment of hypotension between conventionally monitored patients (Group CM) and those receiving HPI (Group CM + HPI) monitoring by ClearSight, in a population of healthy laboring women who receive epidural analgesia.

Outcome Measures

OutcomeResultp-value
PRIMARY
Time-to-treatment of Hypotension (Minutes)
21.8; 23.1
PRIMARY
Ease of Use by Clinical Staff
1; 1; 4; 4; 6; 7
PRIMARY
Ease of Hypotension Detection by Clinical Staff
1; 1; 4; 3; 0; 2
PRIMARY
Satisfaction of ClearSight Use by Clinical Staff
1; 0; 5; 5; 7; 8
SECONDARY
Total Time in Hypotension With Mean Arterial Pressure (MAP) <65 mmHg (in Minutes)
12.5; 7.7
SECONDARY
Nausea (Yes/No)
5; 7; 9; 8
SECONDARY
Vomiting (Yes/No)
3; 0; 11; 16
SECONDARY
Total Phenylephrine, mg
223.3; 506.7
SECONDARY
Total Ephedrine, mg
29.8; 23.3
SECONDARY
Total Intravenous Fluids, mL
550.0; 535.7
SECONDARY
Total Number of Reported Changes in Fetal Heart Rate Category (From Healthy to Deceleration or Excelleration)
8; 6; 6; 9
SECONDARY
Fetal Heart Rate Decelerations Within 1 Hour of Initiation of ELA
5; 5; 9; 10

Eligibility Criteria

Inclusion Criteria

  • Pregnant
  • Age ≥ 18 years of age
  • Planning vaginal delivery
  • Receiving epidural labor analgesia (ELA)

Exclusion Criteria

  • Non-reassuring fetal tracing at the time of ELA request
  • Contraindications to ELA
  • Significant cardiac arrhythmias or aortic regurgitation
  • Arrhythmia
  • Treatment with antihypertensive medications
  • Pre-eclampsia with or without severe features
  • Preoperative infection
  • Inability to use ClearSight device for any reason
  • Non-English fluency
  • Sustains unintentional dural puncture
  • Incomplete data
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05906368). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search